{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:49:59Z","timestamp":1792226999136,"version":"4.4.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40620-020-00796-z","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T02:34:52Z","timestamp":1594348492000},"page":"995-999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Uric acid and risk of diabetic kidney disease"],"prefix":"10.1093","volume":"33","author":[{"given":"Michael","family":"Mauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-4304","authenticated-orcid":false,"given":"Alessandro","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"796_CR1","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","volume":"365","author":"IH de Boer","year":"2011","unstructured":"de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B (2011) Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365:2366\u20132376. https:\/\/doi.org\/10.1056\/NEJMoa1111732","journal-title":"N Engl J Med"},{"key":"796_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860. https:\/\/doi.org\/10.1056\/NEJMoa011303","journal-title":"N Engl J Med"},{"key":"796_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH (2016) Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316:602\u2013610. https:\/\/doi.org\/10.1001\/jama.2016.10924","journal-title":"JAMA"},{"key":"796_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B (2018) IDF diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271\u2013281. https:\/\/doi.org\/10.1016\/j.diabres.2018.02.023","journal-title":"Diabetes Res Clin Pract"},{"key":"796_CR5","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.2337\/db09-0014","volume":"58","author":"P Hovind","year":"2009","unstructured":"Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH (2009) Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 58:1668\u20131671","journal-title":"Diabetes"},{"key":"796_CR6","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1093\/ndt\/gfp740","volume":"25","author":"DI Jalal","year":"2010","unstructured":"Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, Rewers M, Snell-Bergeon JK (2010) Serum uric acid levels predict the development of albuminuria over 6\u00a0years in patients with type 1 diabetes: findings from the coronary artery calcification in type 1 diabetes study. Nephrol Dial Transpl 25:1865\u20131869","journal-title":"Nephrol Dial Transpl"},{"key":"796_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2873","author":"A Pacilli","year":"2017","unstructured":"Pacilli A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S (2017) Group AM-AS: epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: the AMD-Annals initiative. Diabetes Metab Res Rev. https:\/\/doi.org\/10.1002\/dmrr.2873","journal-title":"Diabetes Metab Res Rev"},{"key":"796_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2337\/dc11-1346","volume":"35","author":"G Zoppini","year":"2012","unstructured":"Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E (2012) Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 35:99\u2013104. https:\/\/doi.org\/10.2337\/dc11-1346","journal-title":"Diabetes Care"},{"key":"796_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2337\/dc10-0227","volume":"33","author":"LH Ficociello","year":"2010","unstructured":"Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS (2010) High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 33:1337\u20131343","journal-title":"Diabetes Care"},{"key":"796_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00592-015-0825-x","volume":"53","author":"Y Hayashino","year":"2016","unstructured":"Hayashino Y, Okamura S, Tsujii S, Ishii H (2016) Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. Acta Diabetol 53:599\u2013607. https:\/\/doi.org\/10.1007\/s00592-015-0825-x","journal-title":"Acta Diabetol"},{"key":"796_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/dmrr.2768","volume":"32","author":"YH Chang","year":"2016","unstructured":"Chang YH, Lei CC, Lin KC, Chang DM, Hsieh CH, Lee YJ (2016) Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study. Diabetes Metab Res Rev 32:557\u2013564. https:\/\/doi.org\/10.1002\/dmrr.2768","journal-title":"Diabetes Metab Res Rev"},{"key":"796_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1681\/ASN.2005010063","volume":"16","author":"RJ Johnson","year":"2005","unstructured":"Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W, Roncal C, Sanchez-Lozada LG, Gersch M, Rodriguez-Iturbe B, Kang DH, Acosta JH (2005) Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 16:1909\u20131919","journal-title":"J Am Soc Nephrol"},{"key":"796_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101\u20131106","journal-title":"Hypertension"},{"key":"796_CR14","doi-asserted-by":"publisher","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","volume":"282","author":"M Mazzali","year":"2002","unstructured":"Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ (2002) Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991\u2013F997","journal-title":"Am J Physiol Renal Physiol"},{"key":"796_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51\u201359","journal-title":"Am J Kidney Dis"},{"key":"796_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388\u20131393","journal-title":"Clin J Am Soc Nephrol"},{"key":"796_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","volume":"58","author":"Y Miao","year":"2011","unstructured":"Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ (2011) Effect of a reduction in uric acid on renal outcomes during Losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II Antagonist Losartan Trial. Hypertension 58:2\u20137","journal-title":"Hypertension"},{"key":"796_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Investigators E-RO: empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"796_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Investigators E-RO: empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"796_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, Investigators CT (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"796_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41581-019-0174-z","volume":"15","author":"Y Sato","year":"2019","unstructured":"Sato Y, Feig DI, Stack AG, Kang DH, Lanaspa MA, Ejaz AA, Sanchez-Lozada LG, Kuwabara M, Borghi C, Johnson RJ (2019) The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol 15:767\u2013775. https:\/\/doi.org\/10.1038\/s41581-019-0174-z","journal-title":"Nat Rev Nephrol"},{"key":"796_CR22","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M (2020) PERL Study Group: serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 382:2493\u20132503. https:\/\/doi.org\/10.1056\/NEJMoa1916624","journal-title":"N Engl J Med"},{"key":"796_CR23","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"S Badve","year":"2020","unstructured":"Badve S, Pascoe E, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoysa J, Douglas B, Faull R, Harris D, Hawley C, Jones GR, Kanellis J, Palmer S, Perkovic V, Rangan G, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW (2020) CKD-FIX Study Investigators: effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382:2504\u20132513. https:\/\/doi.org\/10.1056\/NEJMoa1915833","journal-title":"N Engl J Med"},{"key":"796_CR24","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.2337\/dc19-0342","volume":"42","author":"M Afkarian","year":"2019","unstructured":"Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, Crandall JP, de Boer IH, Elliott TG, Galecki AT, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Lingvay I, Maahs DM, McGill JB, Molitch ME, Perkins BA, Pop-Busui R, Pragnell M, Rosas SE, Rossing P, Senior P, Sigal RJ, Spino C, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, Doria A (2019) PERL Study Group: preventing early renal loss in diabetes (PERL) Study: a randomized double-blinded trial of allopurinol\u2014rationale, design, and baseline data. Diabetes Care 42:1454\u20131463. https:\/\/doi.org\/10.2337\/dc19-0342","journal-title":"Diabetes Care"},{"key":"796_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"F National Kidney","year":"2012","unstructured":"National Kidney F (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60:850\u2013886. https:\/\/doi.org\/10.1053\/j.ajkd.2012.07.005","journal-title":"Am J Kidney Dis"},{"key":"796_CR26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.amjmed.2006.06.040","volume":"120","author":"HK Choi","year":"2007","unstructured":"Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442\u2013447. https:\/\/doi.org\/10.1016\/j.amjmed.2006.06.040","journal-title":"Am J Med"},{"key":"796_CR27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.kint.2016.11.025","volume":"91","author":"AJ Ahola","year":"2017","unstructured":"Ahola AJ, Sandholm N, Forsblom C, Harjutsalo V, Dahlstrom E, Groop PH, FinnDiane Study G (2017) The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes. Kidney Int 91:1178\u20131185. https:\/\/doi.org\/10.1016\/j.kint.2016.11.025","journal-title":"Kidney Int"},{"key":"796_CR28","doi-asserted-by":"publisher","first-page":"e1002725","DOI":"10.1371\/journal.pmed.1002725","volume":"16","author":"DM Jordan","year":"2019","unstructured":"Jordan DM, Choi HK, Verbanck M, Topless R, Won HH, Nadkarni G, Merriman TR, Do R (2019) No causal effects of serum urate levels on the risk of chronic kidney disease: a Mendelian randomization study. PLoS Med 16:e1002725. https:\/\/doi.org\/10.1371\/journal.pmed.1002725","journal-title":"PLoS Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00796-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-020-00796-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00796-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:28Z","timestamp":1777564588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/33\/5\/995\/8328454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00796-z","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The PERL trial was conducted in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the ethical committees of all institutions participating in the study, and all participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}